Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy

DISEASE CHARACTERISTICS: * Histologically confirmed adenocarcinoma of the prostate with any of the following: * Prostate-specific antigen ≥ 10 mg/dL * Bone disease * Bidimensional soft tissue disease * Evaluable disease * Advanced disease AND failed prior primary androgen ablation therapy, including anti-androgen withdrawal * Disease not amenable to local curative treatment * No known brain metastases PATIENT CHARACTERISTICS: * ECOG performance status 0-1 * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Creatinine \< 2.0 mg/dL * SGPT and SGOT \< 1.5 times upper limit of normal (ULN) * Bilirubin ≤ ULN * Hemoglobin ≥ 10 g/dL * Ejection fraction ≥ 50% * Peripheral neuropathy ≤ grade 1 * Fertile patients must use effective contraception during and for 3 months after completion of study treatment * No previous history of or concurrent malignancy, except for any of the following: * Inactive nonmelanoma skin cancer * Disease-free for five or more years * Adequately treated stage I or II cancer from which patient is currently in complete remission * No other serious medical illness that would limit survival to less than 3 months * No psychiatric condition that would prevent informed consent * No active, uncontrolled bacterial, viral, or fungal infection * No hemorrhagic disorder * No history of severe hypersensitivity reaction to other drugs formulated with polysorbate 80 PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No new hormonal treatment within the past 4 weeks * No prior immunotherapy, chemotherapy, or bone-seeking radiopharmaceuticals (e.g., strontium chloride Sr 89 or samarium Sm 153 lexidronam pentasodium) * Prior bisphosphonates allowed * At least 2 weeks since prior radiotherapy * No other concurrent chemotherapy